DAWN试验中连续ASPECTS:梗死演变与临床影响
DAWN试验纳入206例晚时间窗取栓患者,独立评估基线及24小时ASPECTS。基线ASPECTS中位8.0,24小时降至6.0,中位变化−1。血管内治疗、基线血糖<150 mg/dL、较低基线NIHSS和较大年龄预测较高24小时ASPECTS,24小时ASPECTS预测90天良好预后。
要点
- 晚时间窗取栓患者基线ASPECTS谱较宽,24小时内梗死可进展。
- 血管内治疗显著影响24小时ASPECTS,治疗组无变化比例高于药物组。
- 24小时ASPECTS独立预测90天良好临床预后。
核心结论
- DAWN试验中基线小梗死核心患者基线ASPECTS范围较宽,24小时ASPECTS受血管内治疗显著影响并预测良好临床预后。
研究设计与样本
- DAWN试验影像核心实验室独立评分基线和24小时ASPECTS,纳入206例受试者,平均年龄70.0±13.7岁,女性54.9%(n=113),基线NIHSS中位17(13,21)。
主要发现
- 基线ASPECTS中位8.0(7–8),其中92/205(44.9%)为0–7,113/205(55.1%)为8–10。
- 24小时ASPECTS中位6.0(4–8),ASPECTS变化中位−1,范围−8至+2。
- 较高基线ASPECTS与较大年龄(每10年OR 1.26,95%CI 1.02–1.55,P=0.030)和高脂血症(OR 1.84,95%CI 1.06–3.19,P=0.031)独立相关。
- 较高24小时ASPECTS由血管内治疗(OR 2.76,95%CI 1.58–4.81,P=0.0004)、基线血糖<150 mg/dL(OR 2.86,95%CI 1.50–5.46,P=0.001)、较低基线NIHSS(OR 0.93,95%CI 0.89–0.98,P=0.010)和较大年龄(每10年OR 1.25,95%CI 1.01–1.55,P=0.041)预测;颈内动脉病变位置与24小时ASPECTS负相关(OR 0.47,95%CI 0.24–0.89,P=0.021)。
- 24小时ASPECTS预测90天良好临床预后(mRS 0–2,OR 1.46,95%CI 1.08–1.96,P=0.014);广泛梗死演变(ASPECTS下降≥6)发生14/201(7.0%)。
关键数值与推荐
- 基线血糖≥150 mg/dL预测ASPECTS下降≥4分(OR 2.78,95%CI 1.21–6.35,P=0.016),颈内动脉闭塞亦为预测因素(OR 2.49,95%CI 1.05–5.88,P=0.038)。
- ASPECTS变化受治疗组影响(Wilcoxon检验P=0.001),血管内治疗组42/105(40.0%)无ASPECTS变化,药物治疗组仅20/96(20.8%)。
临床怎么用
- 在晚时间窗取栓决策中,可关注基线ASPECTS及24小时ASPECTS动态变化。
- 血管内治疗与24小时ASPECTS改善相关,基线血糖<150 mg/dL、较低NIHSS和较大年龄亦与较高24小时ASPECTS相关。
- 24小时ASPECTS较高与90天良好预后相关,颈内动脉闭塞和基线血糖≥150 mg/dL与梗死进展相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The impact of baseline ischemia on Alberta Stroke Program Early CT Score (ASPECTS) and evolution over 24 hours may be distinct in late thrombectomy. We analyzed predictors of serial ASPECTS and clinical outcomes in the DAWN trial (Diffusion-Weighted Imaging or CTP Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention With Trevo). METHODS: The DAWN Imaging Core Laboratory independently scored ASPECTS at baseline and 24 hours. Descriptive statistics characterized ASPECTS on computed tomography/magnetic resonance imaging at baseline and 24 hours, delineating ASPECTS change over 24 hours. RESULTS: 206 subjects (mean age 70.0±13.7 years; 54.9% (n=113) female; baseline National Institutes of Health Stroke Scale median (interquartile range) 17 (13, 21) were included. Baseline ASPECTS was median (interquartile range) 8.0 (7–8), with 92/205 (44.9%) between 0 and 7 and 113/205 (55.1%) 8 and 10. 24-hour ASPECTS was median 6.0 (4–8), with ASPECTS change or infarct evolution having median −1, ranging from −8 to +2. Multivariable logistic regression showed older age (odds ratio [OR] for 10-year interval, 1.26 [95% CI, 1.02–1.55], P=0.030) and dyslipidemia (OR, 1.84 [95% CI, 1.06–3.19], P=0.031) were independently associated with higher baseline ASPECTS. Higher 24-hour ASPECTS was predicted by endovascular treatment (OR, 2.76 [95% CI, 1.58–4.81], P=0.0004), baseline glucose <150 mg/dL (OR, 2.86 [95% CI, 1.50–5.46], P=0.001), lower baseline National Institutes of Health Stroke Scale (OR, 0.93 [95% CI, 0.89–0.98], P=0.010), and older age (OR for 10-year interval, 1.25 [95% CI, 1.01–1.55], P=0.041). Internal carotid artery lesion location (OR, 0.47 [95% CI, 0.24–0.89], P=0.021) was inversely related to 24-hour ASPECTS. Good clinical outcome (day 90 modified Rankin Scale score 0–2) was predicted by 24-hour ASPECTS (OR, 1.46 [95% CI, 1.08–1.96], P=0.014). Extensive infarct evolution (ASPECTS decrease ≥6) occurred in 14/201 (7.0%). Elevated baseline serum glucose ≥150 mg/dL was a predictor of ASPECTS decrease of ≥4 points (OR, 2.78 [95% CI, 1.21–6.35] P=0.016) as was internal carotid artery occlusion (OR, 2.49 [95% CI, 1.05–5.88]; P=0.038). ASPECTS change was influenced by treatment arm (P=0.001 by Wilcoxon), including 0 ASPECTS change in 42/105 (40.0%) of the endovascular arm and only 20/96 (20.8%) of the medical arm. CONCLUSIONS: DAWN subjects enrolled with small infarct cores had a broad range of baseline ASPECTS. Twenty-four-hour ASPECTS, strikingly influenced by endovascular therapy, predicted good clinical outcomes. REGISTRATION: https://www.clinicaltrials.gov; Unique identifier: NCT02142283.
引用
- Liebeskind DS, Saber H, Bhuva P, et al. Serial ASPECTS in the DAWN Trial: Infarct Evolution and Clinical Impact. Stroke. 2021. PMID: 34281376. doi:10.1161/STROKEAHA.120.033477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。